Rocket boosted as FDA alignment on pivotal gene therapy trial design sends stock skyward

[cafead]

via Rocket Pharmaceuticals has reached alignment with the FDA on the design of a pivotal phase 2 rare disease trial, positioning it to run a 12-patient study that could support accelerated approval of a gene therapy.

article source